Financial Performance - Total revenue for the year ended December 31, 2025, reached $535.914 million, a significant increase of 74% compared to $307.748 million in 2024[3]. - Gross profit for the same period was $77.437 million, up from $48.934 million, reflecting a gross margin improvement[3]. - Net profit attributable to shareholders was $32.055 million, compared to $11.168 million in the previous year, marking a 187% increase[4]. - Basic and diluted earnings per share increased to $12.65 from $4.41, indicating strong profitability growth[4]. - The company's net asset value rose to $307.881 million, up from $260.512 million, demonstrating solid financial health[6]. - The company reported a total comprehensive income of $47.369 million, significantly higher than $8.494 million in the previous year[4]. - The group's profit before tax for 2025 was $44,270,000, compared to $16,050,000 in 2024, indicating a substantial increase of about 176%[23]. - The net profit attributable to shareholders for 2025 was $32,055,000, significantly higher than $11,168,000 in 2024, marking an increase of about 187%[28]. - The revenue from the China market for 2025 was $421,307,000, a substantial increase from $233,230,000 in 2024, representing a growth of approximately 80.5%[18]. - The revenue from animal health products increased from 72% in 2024 to 82% in 2025, while the revenue from the antibiotic product decreased from 28% to 18%[38]. Assets and Liabilities - Total assets increased to $561.664 million from $422.214 million, with total liabilities decreasing from $161.702 million to $153.783 million[6]. - Total assets as of December 31, 2025, amounted to $461,664,000, up from $422,214,000 in 2024, reflecting a growth of approximately 9.3%[16][18]. - The total liabilities for the group were $153,783,000 as of December 31, 2025, compared to $161,702,000 in 2024, showing a decrease of about 4.5%[16][18]. - Net debt decreased to $7.3 million in 2025 from $36.8 million in 2024, resulting in a debt-to-equity ratio of 0.02 compared to 0.14 in 2024[41]. - Total borrowings as of December 31, 2025, amounted to $47.2 million, down from $69.2 million as of December 31, 2024, with secured borrowings representing 12.8% of total borrowings[44]. - The group’s net secured borrowings decreased from $18.8 million in 2024 to $6 million in 2025[44]. Cash Flow and Investments - Cash and cash equivalents increased to $39.831 million from $32.381 million, providing liquidity for future investments[5]. - As of December 31, 2025, the group held cash and cash equivalents of $39.8 million, an increase of $7.4 million from $32.4 million as of December 31, 2024[43]. - Investments in joint ventures increased to $105.558 million from $98.717 million, indicating ongoing strategic partnerships[5]. - The profit from joint ventures increased from $500,000 in 2024 to $2.3 million in 2025[39]. Corporate Governance and Compliance - The company has not adopted any new accounting standards that would significantly impact the financial statements for the reporting period[9]. - The group’s financial statements for the year ending December 31, 2025, were reviewed by KPMG, confirming consistency with the draft financial statements[51]. - The company maintained strict corporate governance standards, adhering to the principles and disclosure requirements of the Hong Kong Stock Exchange[49]. Dividends and Shareholder Returns - The company did not declare a final dividend for the year ending December 31, 2025, consistent with the previous year[26]. - The board resolved not to declare any dividends for the year ending December 31, 2025, consistent with the previous year[47]. Employment and Workforce - The group employed approximately 900 employees in China and Hong Kong as of December 31, 2025, with compensation based on performance and market levels[46]. Market and Competitive Landscape - ECI Metro's sales of excavators, generators, and parts rose by 23.4% in 2025, despite a decline in overall profit margins due to competition[39]. - The company remains cautiously optimistic about its performance in 2026, despite uncertainties in the recovery of the Chinese livestock industry[40].

CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 （於百慕達註冊成立之成員有限責任公司） （股份代號：3839） 董事名單與其角色和職能 正大企業國際有限公司董事會及各委員會成員名單與其角色和職能載列如下: | | 審核委員會 | | 薪酬委員會 | 提名委員會 | 企業管治委員會 | | --- | --- | --- | --- | --- | --- | | 董事長及執行董事 | | | | | | | 謝吉人先生 | | | | | | | 執行董事 | | | | | | | 李紹慶先生 | | | | 成員 | | | 謝杰人先生 | | | | | 成員 | | 馬德壽先生 （行政總裁） | | | 成員 | | 成員 | | 非執行董事 | | | | | | | Kobboon Srichai 女士 | | | | | | | 池添洋一先生 | | | | | | | 獨立非執行董事 | | | | | | | Surasak Rounroengrom 先生 | | 成員 | | 主席 | | | 鄭毓和先生 | | 主席 | 主席 ...

董事、行政總裁及 董事會委員會組成之變更 正大企業國際有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈， 下列變更自二零二六年二月二十四日起生效： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 （於百慕達註冊成立之成員有限責任公司） （股份代號：3839） 董事調任、 李紹祝先生及李紹慶先生各自已確認，其與董事會並無意見分歧，亦無任何有關其辭任之事宜 須請本公司股東垂注。 謝先生、Srichai 女士及馬先生之履歷詳情如下： 謝吉人先生，61 歲，自二零一四年九月出任本公司之董事長。彼於二零一四年九月至二零二六 年二月期間曾擔任本公司非執行董事，並自二零二六年二月二十四日起調任為本公司執行董事。 彼於二零一四年九月至二零二四年二月期間曾擔任本公司提名委員會主席。彼為本公司若干附 屬公司之董事。謝先生擁有跨國性投資及 ...

Core Viewpoint - The company, Charoen Pokphand Enterprises International (03839.HK), will hold a board meeting on February 24, 2026, to approve the annual performance for the year ending December 31, 2025, and to consider the distribution of a final dividend, if any [1] Group 1 - The board meeting is scheduled for February 24, 2026 [1] - The meeting will focus on approving the annual performance for the fiscal year ending December 31, 2025 [1] - The company will also consider the distribution of a final dividend during this meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司（「本公司」）董事會（「董事會」）謹此宣佈將於二零 二六年二月二十四日（星期二）舉行董事會會議，藉以（其中包括）批准本公司 及其附屬公司截至二零二五年十二月三十一日止年度之年度業績及考慮派發末期 股息（如有）。 承董事會命 董事 李紹祝 香港，二零二六年二月六日 於本公告日期，董事會包括謝吉人先生（董事長及非執行董事）、李紹慶先生、李紹祝 先生、謝杰人先生、馬德壽先生（各人均為執行董事）、池添洋一先生（非執行董事）、 Surasak Rounroengrom 先生、鄭毓和先生、高明東先生及章曼琪女士（各人均為獨立非執 行董事）。 正大企業國際有限公司 （於百慕達註冊成立之成員有限責任公司） （股份代號：3839） 董事會會議召開日期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 正大企業國際有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 足夠公眾持股量的確認(註4) | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03839 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,738,922.3 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,7 ...

Core Viewpoint - The company anticipates a decline in demand for its animal health products due to a slowdown in China's livestock industry, but expects overall profit growth for the fiscal year 2025 [1] Group 1: Financial Performance - The company projects a shareholder's net profit of approximately $32 million for the year ending December 31, 2025, a significant increase from $11.2 million for the year ending December 31, 2024 [1] - The profit growth is primarily attributed to a substantial increase in revenue, reflecting the successful implementation of a key strategy focused on developing large customer sales [1] Group 2: Revenue Expectations - The company's quarterly revenue for the three months ending December 31, 2025, is expected to remain at a similar level to that of the three months ending September 30, 2025 [1]

Core Viewpoint - The company anticipates a significant increase in net profit attributable to shareholders, projecting approximately $32 million for the year ending December 31, 2025, compared to $11.2 million for the year ending December 31, 2024, driven by substantial revenue growth and successful implementation of key sales strategies targeting major clients [1]. Financial Performance - Projected net profit for the year ending December 31, 2025, is approximately $32 million [1] - Net profit for the year ending December 31, 2024, is recorded at $11.2 million [1] - The increase in profit is attributed to a significant rise in revenue [1]

Core Viewpoint - The company anticipates a decrease in demand for its animal health products due to a slowdown in China's livestock industry starting from the third quarter of 2025, yet expects a significant increase in overall profit for the fiscal year 2025 [1] Group 1: Financial Performance - The company projects a shareholder's net profit of approximately $32 million for the fiscal year ending December 31, 2025, compared to $11.2 million for the fiscal year ending December 31, 2024 [1] - The growth in profit is primarily attributed to a substantial increase in revenue, reflecting the successful implementation of a key strategy focused on developing large customer sales [1] Group 2: Revenue Expectations - The company's quarterly revenue for the three months ending December 31, 2025, is expected to remain at a similar level to that of the three months ending September 30, 2025 [1]

CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 （於百慕達註冊成立之成員有限責任公司） (股份代號：3839) 內幕消息 二零二五年度初步業績之預估盈利 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告由正大企業國際有限公司（「本公司」連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09（2）條和證券及期貨 條例（香港法例第571章）第XIVA部項下的內幕消息條文（定義見上市規則）而作出。 由於中國畜牧業放緩，我們的動保化藥產品需求也自二零二五年第三季隨之減少。儘 管如此，本集團預期二零二五年度綜合溢利仍將錄得增長。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據 初步資料，本集團預期截至二零二五年十二月三十一日止年度錄得股東應佔綜合溢利 約為3,200萬美元，相比截至二零二四年十二月三十一日止年度則錄得1,12 ...